{
    "clinical_study": {
        "@rank": "30317", 
        "brief_summary": {
            "textblock": "To conduct a double-blind, randomized, dose ranging study of an orally administered low dose\n      interferon alfa-n3 (IFN-An3) immunomodulator in the treatment of symptomatic HIV+ subjects."
        }, 
        "brief_title": "Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT).\n\n          -  Didanosine (ddI)\n\n        Patients must have:\n\n          -  Seropositivity to HIV-1 by ELISA and Western blot.\n\n          -  At least 1 of the HIV-related clinical symptoms or opportunistic infections listed in\n             protocol.\n\n          -  Written informed consent.\n\n          -  If already on zidovudine (AZT) or didanosine (ddI), must have been on this therapy\n             for at least 75 of the 90 days prior to study entry.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT).\n\n          -  Didanosine (ddI)\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Major active opportunistic infection requiring active care within 2 weeks of study\n             entry.\n\n          -  Evidence of chronic hepatitis with severe liver dysfunction:\n\n          -  albumin < 2 g/dl and SGOT or SGPT > 5 x upper limit of normal prothrombin time > 1.5\n             x upper limit of normal).\n\n          -  Other active gastrointestinal, renal, respiratory, endocrine, hematologic,\n             cardiovascular, neurologic, or psychiatric disorder.\n\n          -  Transfusion dependency defined as requiring > 1 unit of packed red blood cells (RBC)\n             per month within 3 months prior to study entry.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Experimental medications other than didanosine (ddI).\n\n          -  Chronic prophylactic use of any topical or systemic fungal medication such as\n             ketoconazole, fluconazole, or clotrimazole.\n\n          -  Chronic prophylactic use of any topical or systemic anti-viral medication such as\n             acyclovir or ganciclovir except zidovudine (AZT) or didanosine (ddI).\n\n        Patients with the following are excluded:\n\n          -  Asymptomatic at study entry.\n\n          -  Presence of antibodies to interferon due to prior therapy.\n\n          -  Hospitalization within 2 weeks of study entry.\n\n          -  Transfusion dependency.\n\n          -  Unwilling or unable to give informed consent.\n\n          -  Evidence of any concurrent organ dysfunction listed in Exclusion Co-Existing\n             Conditions.\n\n          -  Unlikely or unable to comply with the requirements of the protocol.\n\n        Prior Medication:\n\n        Excluded within 6 weeks of study entry:\n\n          -  Interferons.\n\n          -  Excluded within 45 days of study entry:\n\n          -  Immunosuppressive agents.\n\n          -  Chemotherapy.\n\n          -  Steroids.\n\n          -  Immunomodulators.\n\n          -  Isoprinosine.\n\n          -  BCG vaccine.\n\n        Prior Treatment:\n\n        Excluded within 2 weeks of study entry:\n\n          -  Hospitalization.\n\n        Active intravenous (IV) drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002018", 
            "org_study_id": "069B", 
            "secondary_id": "90-355ME"
        }, 
        "intervention": {
            "intervention_name": "Interferon alfa-n3", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons"
            ]
        }, 
        "keyword": "Interferon Type I", 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "Mount Sinai Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002018"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Interferon Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1993"
    }, 
    "geocoordinates": {
        "Mount Sinai Med Ctr": "40.714 -74.006"
    }
}